RxDoctor Payments Data

Jessica Glossip, PA

Physician Assistant · Pinehurst, NCNPI 1053838326

Payments from drug & device makers

$5,635in general payments, 2019–2025

Across 314 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$816
  • AbbVie$675
  • Lilly USA, LLC$493
  • Boehringer Ingelheim$438
  • Merck$321
  • Novo Nordisk$317
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$5,635100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,635 in reported general payments places this provider in the 90th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$43,838
Medicare patients
103
Services billed
1,301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin42$37,609
MounjaroTirzepatide15$36,817
OzempicSemaglutide22$35,913
Xigduo XrDapaglifloz Propaned/Metformin31$26,894
FarxigaDapagliflozin Propanediol26$26,644
TrulicityDulaglutide25$26,541
JanuviaSitagliptin Phosphate31$24,648
XareltoRivaroxaban20$23,047
RybelsusSemaglutide16$22,968
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$14,461
VascepaIcosapent Ethyl23$13,427
MyrbetriqMirabegron26$12,921
EntrestoSacubitril/Valsartan16$10,495
Synjardy XrEmpagliflozin/Metformin Hcl15$9,852
GemtesaVibegron13$6,347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$493$63,35840 claims
Novo NordiskOzempic, Rybelsus$317$58,88138 claims
Boehringer IngelheimJardiance, Synjardy Xr$438$47,46157 claims
AstraZenecaFarxiga$816$26,64426 claims
MerckJanuvia$321$24,64831 claims
Johnson & JohnsonXarelto$181$23,04720 claims
GSKTrelegy Ellipta, Arnuity Ellipta$243$17,62136 claims
Astellas Pharma US IncMyrbetriq$66$12,92126 claims
NovartisEntresto$53$10,49516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Pinehurst

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →